Raghuveer Chandrashekhar

Mr. Raghuveer Chandrashekhar

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2020 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Hongwu WangHongwu Wang
Hongwu Wang
RCRaghuveer Chandrashekhar
Raghuveer Chandrashekhar
JRJosiah Rippetoe
Josiah Rippetoe
MGMustafa Ali Ghazi
Mustafa Ali Ghazi
In this review, we present a narrative synthesis of studies on the use of focal muscle vibration (FMV) in stroke rehabilitation with a focus on vibration device, parameters, and protocols. A search was conducted via PubMed, SCOPUS, PEDro, REHABDATA, and Web of Science using the keywords “stroke and focal vibration” or “focal muscle vibration”. Inclusion and exclusion criteria to select the articles were determined. Twenty-two articles involving FMV and stroke were included in this review. Eight different vibration devices were used in the 19 articles that reported the vibration apparatuses. The vibration frequencies ranged from 30 Hz to 300 Hz with amplitudes ranging from 0.01 mm to 2 mm. The vibration treatment frequency ranged from a single treatment to 5 days/week. The session duration ranged from 14 s to 60 min/session with a duration of a single treatment to eight weeks. Twenty different muscles were targeted with 37 different outcome measures used to assess the effects of FMV. The clinical applications of FMV were not confirmed based on available evidence. More research is needed to improve the FMV technology, guide the selection of vibration parameters, optimize the vibration dosage, and develop standardized protocols for FMV therapy in patients with stroke.

RCRaghuveer Chandrashekhar
Raghuveer Chandrashekhar
Hongwu WangHongwu Wang
Hongwu Wang
CDCarol Dionne
Carol Dionne
SJShirley James
Shirley James
JBJenni Burzycki
Jenni Burzycki
People with diabetic peripheral neuropathy (DPN) experience a lower quality of life caused by associated pain, loss of sensation and mobility impairment. Current standard care for DPN is limited and lacking. This study explores the benefits of 4-week, in-home wearable focal muscle vibration (FMV) therapy on pain, balance, mobility, and sensation in people with DPN. Participants were randomized into three groups and received different FMV intensities. FMV was applied using a modified MyovoltTM wearable device to the tibialis anterior, distal quadriceps, and gastrocnemius/soleus muscles on both lower limbs for three days a week over four weeks. The outcomes included pain, balance, mobility, sensation, device usage log, feedback survey, and a semi-structured interview. In all, 23 participants completed the study. The results showed significant improvement in average pain (Pre: 4.00 ± 2.29; Post: 3.18 ± 2.26; p = 0.007), pain interference with walking ability (Pre: 4.14 ± 3.20; Post: 3.09 ± 1.976; p = 0.03), and standard and cognitive Timed Up-and-Go scores (Pre: 13.75 ± 5.34; Post: 12.65 ± 5.25; p = 0.04; Pre: 15.12 ± 6.60; Post: 12.71 ± 5.57; p = 0.003, respectively); the overall pain improvement was trending towards significance (Pre: 3.48 ± 2.56; Post: 2.87 ± 1.85; p = 0.051). Balance and sensations improved but not significantly. There was a trend towards significance (p = 0.088), correlation (r = 0.382) between changes in balance and baseline pain. The participants were highly satisfied with wearable FMV and were 100% compliant. FMV therapy was associated with improved pain, mobility, and sensation. Further study with a larger sample and better outcome measures are warranted.

26 March 2021 in Applied Sciences
Verified
Journal Article
Open access
PDF file
MGMustafa Ali Ghazi
Mustafa Ali Ghazi
JRJosiah Rippetoe
Josiah Rippetoe
RCRaghuveer Chandrashekhar
Raghuveer Chandrashekhar
Hongwu WangHongwu Wang
Hongwu Wang
Focal vibration therapy can provide neurophysiological benefits. Unfortunately, standardized protocols are non-existent. Previous research presents a wide range of protocols with a wide range of effectiveness. This paper is part of a broader effort to identify effective, standardized protocols for focal vibration therapy. In this study, the authors evaluated the vibration characteristics (frequency and peak-to-peak intensity) of four commercially available focal vibration devices: (1) Vibracool (wearable), (2) Novafon (hand-held), (3) Myovolt 3-actuator (wearable), and (4) Myovolt 2-actuator (wearable). An accelerometer was used for the measurements. Measurements were made under the following two conditions: (a) when the devices were free, i.e., unconstrained vibration, and (b) when the devices were strapped to the human body, i.e., constrained vibration. In the free vibration condition, frequency ranged from 120 to 225 Hz and peak-to-peak amplitude ranged from 2.0 to 7.9 g’s. When the devices were strapped to the body (constrained), vibration amplitude decreased by up to 65.7%. These results identify effective ranges of focal vibration frequency and amplitude. They illustrate the importance of identifying vibration environment, free or constrained, when quoting vibration characteristics. Finally, the inconsistency output of multi-actuator devices is discussed. These results will guide protocol development for focal vibration and potentially better focal vibration devices.

26 April 2022 in Sensors
Verified
Journal Article
Open access
PDF file
Hongwu WangHongwu Wang
Hongwu Wang
MGMustafa Ali Ghazi
Mustafa Ali Ghazi
RCRaghuveer Chandrashekhar
Raghuveer Chandrashekhar
JRJosiah Rippetoe
Josiah Rippetoe
GDGrace Duginski
Grace Duginski
SJShirley James
Shirley James
Stroke often leads to the significant impairment of upper limb function and is associated with a decreased quality of life. Despite study results from several interventions for muscle activation and motor coordination, wide-scale adoption remains largely elusive due to under-doses and low user compliance and participation. Recent studies have shown that focal vibration has a greater potential to increase and coordinate muscle recruitment and build muscle strength and endurance. This form of treatment could widely benefit stroke survivors and therapists. Thus, this study aimed to design and develop a novel wearable focal vibration device for upper limb rehabilitation in stroke survivors. A user participatory design approach was used for the design and development. Five stroke survivors, three physical therapists, and two occupational therapists were recruited and participated. This pilot study may help to develop a novel sustainable wearable system providing vibration-based muscle activation for upper limb function rehabilitation. It may allow users to apply the prescribed vibratory stimuli in-home and/or in community settings. It may also allow therapists to monitor treatment usage and user performance and adjust the treatment doses based on progression.

11 May 2023 in Sensors
Verified
Journal Article
Open access
PDF file
EHElizabeth S Hile
Elizabeth S Hile
MGMustafa Ali Ghazi
Mustafa Ali Ghazi
RCRaghuveer Chandrashekhar
Raghuveer Chandrashekhar
JRJosiah Rippetoe
Josiah Rippetoe
AFAshley Fox
Ashley Fox
Hongwu WangHongwu Wang
Hongwu Wang
Hallux strength is associated with sports performance and balance across the lifespan, and independently predicts falls in older adults. In rehabilitation, Medical Research Council (MRC) Manual Muscle Testing (MMT) is the clinical standard for hallux strength assessment, but subtle weakness and longitudinal changes in strength may go undetected. To address the need for research-grade yet clinically feasible options, we designed a new load cell device and testing protocol to Quantify Hallux Extension strength (QuHalEx). We aim to describe the device, protocol and initial validation. In benchtop testing, we used eight precision weights to apply known loads from 9.81 to 78.5 N. In healthy adults, we performed three maximal isometric tests for hallux extension and flexion on the right and left sides. We calculated the Intraclass Correlation Coefficient (ICC) with 95% confidence interval and descriptively compared our isometric force–time output to published parameters. QuHalEx benchtop absolute error ranged from 0.02 to 0.41 (mean 0.14) N. Benchtop and human intrasession output was repeatable (ICC 0.90–1.00, p < 0.001). Hallux strength in our sample (n = 38, age 33.5 ± 9.6 years, 53% female, 55% white) ranged from 23.1 to 82.0 N peak extension force and 32.0 to 142.4 N peak flexion, and differences of ~10 N (15%) between toes of the same MRC grade (5) suggest that QuHalEx is able to detect subtle weakness and interlimb asymmetries that are missed by MMT. Our results support ongoing QuHalEx validation and device refinement with a longer-term goal of widespread clinical and research application.

25 July 2024 in Sensors
Verified
Journal Article
Open access
PDF file
RCRaghuveer Chandrashekhar
Raghuveer Chandrashekhar
LFLuciana Fonseca
Luciana Fonseca
Hongwu WangHongwu Wang
Hongwu Wang
Great toe strength (GTS) weakness is linked to declines in balance and mobility. Accurately assessing GTS, particularly great toe extension strength (GTES), is often neglected in clinical evaluations due to cumbersome and subjective methods. This study aims to characterize the force development curve output from the ToeScale and examine GTES variations with age, sex, BMI, and grip strength (GS) using traditional analyses and machine learning (ML). We conducted a pilot, cross-sectional feasibility study with convenience samples. We assessed GS using a hand-grip dynamometer and GTES using the ToeScale. The data analysis included descriptive statistics, correlations, independent samples t-tests, and accuracy and area under the curve (AUC) scores for three ML models. Thirty-one participants (males: 9; females: 22), 14 young (18–24 years) and 17 older (>65 years) adults, participated in the study. Males had significantly higher peak GTES than females in both age groups. The associations of GTES parameters with BMI and GS varied by age and sex. The ML model accuracies and AUC scores were low–moderate but aligned with traditional analyses. Future studies with larger samples and optimized ML models are needed.